Profile data is unavailable for this security.
About the company
MedPlus Health Services Limited is an India-based company. The Company is primarily engaged in retail trading of medicines and general items, wholesale cash and carry and pathological laboratory testing services, wholesale trading and manufacturing of pharmaceutical products, fast-moving consumer goods and beauty products. It operates through three segments: Retail, Diagnostics, and Others. The Retail segment is engaged in retail trading of medicines and general items. The Diagnostics segment is engaged in the diagnostic services. The Other segment includes insurance broking business. The Company operates approximately 4,407 stores in 600 cities distributed across Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, and Maharashtra. Its omni-channel platform enables the Company to service its customers through its stores, as well as its online channels. Its subsidiaries include Optival Health Solutions Private Limited, MHS Pharmaceuticals Private Limited, and others.
- Revenue in INR (TTM)58.29bn
- Net income in INR760.49m
- Incorporated2006
- Employees21.00k
- LocationMedPlus Health Services Ltd5-9-13 707 7Th FloorTaramandal Commercial Com, SaifabadHYDERABAD 500037IndiaIND
- Phone+91 4 067006700
- Websitehttps://www.medplusindia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kimia Farma Tbk PT | 54.65bn | -8.83bn | 19.33bn | 10.71k | -- | 0.6562 | -- | 0.3536 | -297.23 | -304.07 | 1,839.82 | 990.52 | 0.5433 | 2.62 | 4.51 | 892,792,100.00 | -11.23 | -1.82 | -23.01 | -3.22 | 25.74 | 35.14 | -20.67 | -3.08 | 0.3746 | -3.38 | 0.5616 | -- | 7.93 | 3.33 | -737.71 | -- | -9.87 | -- |
| Sipai Health Technology Co, Ltd | 54.83bn | -2.86bn | 42.63bn | 3.25k | -- | 2.41 | -- | 0.7776 | -0.336 | -0.336 | 6.66 | 2.14 | 1.58 | 13.61 | 9.78 | 1,635,929.00 | -7.98 | -- | -13.82 | -- | 9.18 | -- | -5.05 | -- | 1.58 | -- | 0.0386 | -- | 14.39 | -- | 81.34 | -- | -- | -- |
| JZJ Chain Drugstore Corp | 110.41bn | 2.81bn | 47.60bn | 16.65k | 16.73 | 1.45 | -- | 0.4312 | 1.53 | 1.53 | 60.20 | 17.72 | 0.9258 | 2.20 | 20.72 | 559,572.20 | 2.34 | 5.75 | 4.50 | 11.17 | 35.54 | 35.21 | 2.53 | 5.04 | 0.2655 | 2.88 | 0.6563 | 36.62 | 20.84 | 26.84 | 10.72 | 25.41 | 23.62 | -- |
| Genky DrugStores Co Ltd | 103.99bn | 3.57bn | 52.02bn | 1.66k | 14.29 | 1.92 | 7.73 | 0.5003 | 212.46 | 212.46 | 6,180.37 | 1,582.20 | 1.67 | 6.47 | 43.31 | 113,208,300.00 | 5.76 | 4.94 | 8.65 | 7.86 | 20.41 | 20.67 | 3.44 | 2.98 | 0.4102 | 59.82 | 0.4195 | 8.24 | 9.35 | 12.21 | 32.75 | 18.58 | -0.5316 | 0.3968 |
| MedPlus Health Services Ltd | 58.29bn | 760.49m | 80.09bn | 21.00k | 105.78 | -- | 26.00 | 1.37 | 6.34 | 6.34 | 485.51 | -- | -- | -- | -- | 2,775,897.00 | -- | 2.68 | -- | 3.48 | 22.11 | 21.14 | 1.31 | 1.38 | -- | 1.48 | -- | 0.00 | 23.42 | 19.87 | 31.57 | 40.59 | 31.14 | -- |
| Fangzhou Inc | 29.15bn | -10.19bn | 106.79bn | 515.00 | -- | -- | -- | 3.66 | -0.702 | -0.702 | 2.01 | -1.62 | -- | -- | -- | 5,229,344.00 | -- | -- | -- | -- | 20.52 | -- | -34.94 | -- | 0.699 | -- | 30.75 | -- | 10.43 | -- | 48.66 | -- | -- | -- |
| Welcia Holdings Co Ltd | 684.06bn | 12.13bn | 217.46bn | 15.29k | 17.68 | 1.57 | 8.55 | 0.3179 | 106.05 | 106.05 | 5,982.48 | 1,194.41 | 2.11 | 6.31 | 17.08 | 80,917,640.00 | 3.67 | 5.76 | 6.63 | 10.23 | 30.23 | 30.81 | 1.74 | 2.51 | 0.6511 | 38.94 | 0.2343 | 23.97 | 6.38 | 9.33 | -2.14 | 8.71 | 2.59 | 10.12 |
| Dashenlin Pharmaceutical Group Co Ltd | 314.53bn | 10.08bn | 225.80bn | 45.47k | 22.47 | 2.77 | -- | 0.7179 | 0.7445 | 0.7445 | 23.37 | 6.03 | 1.12 | 4.14 | 23.28 | 583,716.30 | 3.90 | 6.57 | 8.15 | 12.63 | 33.80 | 37.51 | 3.47 | 5.54 | 0.598 | 7.15 | 0.5981 | 45.67 | 15.45 | 22.59 | 12.63 | 17.02 | 26.51 | 6.85 |
| Yifeng Pharmacy Chain Co Ltd | 283.48bn | 18.05bn | 372.17bn | 39.65k | 20.58 | 3.06 | -- | 1.31 | 1.26 | 1.26 | 19.77 | 8.46 | 0.9734 | 4.00 | 14.51 | 603,225.00 | 6.72 | 6.93 | 12.76 | 12.47 | 38.47 | 38.73 | 6.90 | 6.71 | 0.8771 | 34.97 | 0.5237 | 26.56 | 13.59 | 26.72 | 11.57 | 27.66 | 25.93 | 33.54 |
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2024 | 8.34m | 6.97% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2024 | 5.68m | 4.75% |
| Steadview Capital Management LLCas of 31 Dec 2023 | 2.67m | 2.24% |
| GIC Pte Ltd. (Investment Management)as of 31 Dec 2023 | 2.67m | 2.24% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 2.59m | 2.17% |
| Goldman Sachs Asset Management LPas of 30 Aug 2024 | 1.36m | 1.14% |
| FIL Investment Management (Singapore) Ltd.as of 30 Sep 2024 | 1.10m | 0.92% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 713.26k | 0.60% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 704.87k | 0.59% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2024 | 438.74k | 0.37% |
